Brief: Zyversa Therapeutics Reports Inducement Grant To Newly Appointed Chief Medical Officer Under Nasdaq Listing Rule 5635(C)(4)
27/01/2023 21:45
Jan 27 (Reuters) - Zyversa Therapeutics Inc ZVSA.O :
* ZYVERSA THERAPEUTICS REPORTS INDUCEMENT GRANT TO NEWLY
APPOINTED
CHIEF MEDICAL OFFICER UNDER NASDAQ LISTING RULE 5635(C)(4)
Source text for Eikon: ID:nGNX6Py60G
Further company coverage: ZVSA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zyversa Therapeutics
See all newsBrief: ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million
Brief: ZyVersa Unveils Potential Of Inflammasome Inhibitors In Combination With GLP-1 Agonists To Address Needs Of People Living With Obesity
Brief: Zyversa Therapeutics Announces Published Data Showing Inflammasome Asc Inhibitor IC 100 Decreases Microglial Inflammasome Activation
Brief: ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative Research And Development Trends For Inflammasome Inhibitors, And Provides Update On Inflammasome ASC Inhibitor IC 100’S Development Status
Brief: Zyversa Therapeutics Files For Prospectus Related To Offer & Resale Of Up To 1.6 Million Shares Of Common Stock By Selling Stockholder - SEC Filing